Elizabeth Czerepak

CIK: 0001263500

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

DCTH

DELCATH SYSTEMS, INC.

Director

RNAZ

Transcode Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (2 total)

DCTH
DELCATH SYSTEMS, INC.
May 13, 2026
Award(A)
Stock Option (right to buy)
Direct
22.5K shares-
DCTH
DELCATH SYSTEMS, INC.
May 15, 2025
Award(A)
Stock Option (right to buy)
Direct
22.5K shares-

		Type	Shares	Price		Ownership
May 13, 2026	DCTH DELCATH SYSTEMS, INC.	Award(A) Stock Option (right to buy)	22,500	-	-	Direct
May 15, 2025	DCTH DELCATH SYSTEMS, INC.	Award(A) Stock Option (right to buy)	22,500	-	-	Direct

1-2 of 2 transactions

About CZEREPAK ELIZABETH

CZEREPAK ELIZABETH (SEC CIK 0001263500) files insider reports with the SEC as Director of DELCATH SYSTEMS, INC. (DCTH) and Director of Transcode Therapeutics, Inc. (RNAZ).

Signal8 holds 3 ownership filings by CZEREPAK ELIZABETH (1 Form 3, 2 Form 4), filed between May 19, 2025 and May 14, 2026. Those filings report 2 transactions, from May 15, 2025 to May 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on CZEREPAK ELIZABETH's filings is in QUEENSBURY, NY.

Recent filings by CZEREPAK ELIZABETH

May 13, 2026: Grant or award of DCTH derivative securities (Form 4, code A).
May 15, 2025: Grant or award of DCTH derivative securities (Form 4, code A).

Other insiders filing for DELCATH SYSTEMS, INC. (DCTH)

Rosalind Advisors, Inc., Director
Sylvester John Richard, Director
Martell Bridget A, Director
SALAMON STEVEN A J, Director
Aharon Gil, Director
Pennell Sandra, Chief Financial Officer

How to read Form 4 transaction codes